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Abstract: Transducin (beta)-like 1X related protein 1 (TBL1XR1/TBLR1) is an integral subunit of the NCoR (nuclear
receptor corepressor) and SMRT (silencing mediator of retinoic acid and thyroid hormone receptors) repressor complexes. It is an evolutionally conserved protein that shares high similarity across all species. TBL1XR1 is essential for
transcriptional repression mediated by unliganded nuclear receptors (NRs) and othe regulated transcription factors
(TFs). However, it can also act as a transcription activator through the recruitment of the ubiquitin-conjugating/19S
proteasome complex that mediates the exchange of corepressors for coactivators. TBL1XR1 is required for the
activation of multiple intracellular signaling pathways. TBL1XR1 germline mutations and recurrent mutations are
linked to intellectual disability. Upregulation of TBL1XR1 is observed in a variety of solid tumors, which is associated
with advanced tumor stage, metastasis and poor prognosis. A variety of genomic alterations, such as translocation,
deletion and mutation have been identified in many types of neoplasms. Loss of TBL1XR1 in B-lymphoblastic leukemia disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance. However, the
mechanisms of other types of genomic changes in tumorogenesis are still not clear. A pre-clinical study has shown
that the disruption of the interaction between TBL1X and β-catenin using a small molecule can inhibit the growth of
AML stem and blast cells both in vitro and in vivo. These findings shed light on the therapeutic potentials of targeting
TBL1XR1 related proteins in cancer treatment.
Keywords: TBL1XR1, TBL1X, corepressor, coactivator, targeted therapy

Introduction
Transducin (beta)-like 1X related protein 1 (TBL1XR1), also known as TBLR1, is an F-box/
WD40-repeat containing protein that was originally isolated as a gene transcript that is preferentially expressed in human CD34+CD38 - cells
[1]. Biochemical studies identified TBL1XR1 as
a core component of NCoR (nuclear receptor
corepressor) and SMRT (silencing mediator of
retinoic acid and thyroid hormone receptors)
repressor complexes that also contain HDAC3
(histone deacetylase 3), TBL1X (transducin
(beta)-like 1X), and GPS2 (G-protein pathway
suppressor 2) [2, 3]. TBL1XR1 is essential in
targeting SMRT/NCoR corepressor complexes
to the promoter of target genes by unliganded
nuclear receptors (NRs) and other regulated
transcription factors (TFs) to mediate repression [3-5]. On the other hand, TBL1XR1 is also
required for transcriptional activation by liganded NRs and other TFs. It serves as a specific
adaptor for the recruitment of the ubiquitinconjugating/19S proteasome complex that

mediates the exchange of corepressors for
coactivators [6, 7]. TBL1XR1 is essential in the
activation of Wnt-β-catenin and NF-κB signaling
pathways [6-10]. De novo deletions and recurrent mutations have been identified in
TBL1XR1gene, which are linked to intellectual
disability (ID) [11-15]. Accumulating evidence
suggests that TBL1XR1 may play an important
role in tumorigenesis, invasion, metastasis, and
developing resistance to therapies [16-22]. This
review will focus on the genomic structure,
expression, and functions of TBL1XR1 and the
pathological states associated with its dysregulation. We will also discuss the therapeutic
potentials of targeting TBL1XR1 and related
pathways.
TBL1XR1 family
Human TBL1XR1 (hTBL1XR1/hTBLR1/IRA1)
gene is located on chromosome 3q26.32 and
consists of 18 exons spanning 178, 119 base
pairs [23]. Two closely related genes, TBLR1X
and TBL1Y, have been cloned and mapped to
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human chromosome X and Y, respectively [24,
25]. TBL1XR1 mRNA is ubiquitously expressed
in many human tissues with higher levels of
expression observed in thyroid, prostate and
breast tissues. The expression of TBL1XR1
overlaps but is distinct from that of TBL1X and
TBL1Y. In addition, an alternatively spliced form
of TBL1XR1 (TBLR1β) has been demonstrated
in human material and it too has a unique pattern of expression [23]. The murine homologue
is structurally similar and is also located on
Chromosome 3. Only one isoform has been
identified in Drosophila (Ebi) and Xenopus
(Xenopus TBL1XR1), which are found more
similar to hTBL1XR1 than to hTBL1X [4, 26].

TBL1XR1 is also susceptible for posttranslational modifications, including phosphoration
and sumoylation. It contains two putative phosphorylation sites (one for CK1/GSK3 and one
for PKCδ) and one SUMO modification site
(Lys497) [7, 9]. Multiple microRNAs (miRNAs)
targeting TBL1XR1 have been identified by
using computational prediction programs, of
which hsa-miR-205 is found to be functional
[30]. In addition, several potential long noncoding RNA (lncRNA) sequences are identified
in the region encompassing the hTBL1XR1
gene. Further studies are needed to understand the roles of these miRNAs and lncRNAs
in the function and regulation of TBL1XR1.

The hTBL1XR1 gene encodes a 514 amino acid
protein with an estimated molecular mass of
55.5 kDa. The β isoform of hTBL1XR1 encodes
a larger protein due to disruption of translation
by alternative splicing. TBL1XR1 protein contains a LisH domain (Lis1 homology domain)
and a F-box-like domain at the amino-terminus
and seven WD40 repeats at the carboxy-terminus [23]. The LisH domain is required for oligomerization, transcriptional repression, and
binding to hypoacetalyted H2B and H4 [27].
Deletion of LisH domain decreases the half life
of TBL1XR1 protein and results in its translocation from nucleus to cytoplasm [28]. The F-boxlike domain is essential for the recruitment of
the ubiquitin/19S proteasome complex to the
transcription units regulated by NRs and TFs for
the degradation of SMRT/NCoR corepressor. It
is also important for the ubiquitin-mediated
degradation of other proteins [28]. The WD40
domains are important for self or heterodimer
protein-protein interaction. The first WD repeat
in TBL1XR1 is essential for its binding to the
RD4 domain of NCoR [3].

TBL1XR1 is primarily localized in nucleus in tissues and many cell lines. However, we have
shown that TBL1XR1 is mostly located in the
cytosol of NIH-3T3 cells and translocates to the
nucleus after induction of apoptosis or growth
arrest. The cytoplasmic pattern is also observed
in several prostate cancer cell lines and primary prostate cancer cells [21, 23].

The structure of TBL1XR1 family is evolutionarily conserved with high degrees of similarity
from yeast to human at the amino acid level
[29]. The N-terminal sequence is totally conserved between Xenopus TBL1XR1 and
hTBL1XR1 and 94% identical to that of hTBL1X.
The WD-40 repeat domain is 98% identical
between Xenopus TBL1XR1 and hTBL1XR1
whereas only 90% identical between the two
human proteins. The high degrees of similarity
in TBL1XR1 family across all the species suggest similar biochemical and molecular functions [4, 23].
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Normal functions of TBL1XR1
TBL1XR1 acts as a transcriptional corepressor
Transcriptional repression mediated by unliganded NRs or other TFs requires a group of corepressors. Biochemical purifications have identified multiple corepressor complexes [2, 3, 31],
which may be used combinatorially and recruited to chromatin in a sequential fasion [7]. The
best characterized is the SMRT/N-CoR/HDAC3
complex that also contains TBL1X, TBL1XR1,
and GPS2 [2, 3]. The corepressor complexes
actively silence basal transcription through
interaction with unliganded NRs. However, the
interaction alone is not sufficient for targeting
the corepressor complexes to target gene promoters and mediating transcriptional repression. As a subunit of the SMRT/NCoR repressor
complexes, TBL1XR1 is found to be essential
for repression by unliganded NRs in both
human cell lines and Xenopus oocytes [3, 4]. A
recent study using small interfering RNA (siRNA)
revealed that TBL1XR1 and TBL1X are functionally redundant and essential for transcriptional repression by thyroid hormone receptor
(THR). Both TBL1XR1 and TBL1X are able to
directly bind to NCoR and SMRT through their
N-terminal and first WD-40 domains. They do
not have direct interaction with unliganded THR
Am J Clin Exp Urol 2015;3(1):13-23
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and HDAC3. They are critical for targeting the
SMRT/NCoR corepressor complexes to chromatin through binding hypoacetylated histones
H2B and H4. Furthermore, this study proposes
a two-interaction, feed-forward working model
for targeting SMRT/N-CoR complexes to chromatin. In brief, the interaction between SMRT/
NCoR and unliganded NRs initiates limited histone deacetylation at the target gene promoter
sites. TBL1X/TBL1XR1 then stabilizes the
association of the SMRT/NCoR complexes with
chromatin by binding the deacetylated histones, resulting in deacetylation of additional
histones. In the final step, the formation of stable complexes and extensive deacetylation
lead to intiation and maintenance of repression. These studies implicate the critical roles
of TBL1XR1 in the formation of stable corepressor complexes on chromatin for mediating
repression [27, 32].
TBL1XR1 acts as an exchange factor of corepressors for coactivators
Transcriptional activation mediated by liganded
NRs and other regulated TFs requires the dismissal of corepressors followed by the recruitment of a series of coactivator complexes harboring specific enzymatic activities. Although
TBL1XR1 and TBL1X are intrinsic components
of the SMRT/NCoR corepressor complexes,
recent study has shown that they both are
required for transcriptional activation by estrogen receptor (ER), androgen receptor (AR), THR,
and peroxisome proliferator-activated receptor
(PPAR). The activation by RAR (retinoid acid
receptor) and AP-1 (activator protein-1) depends
exclusively on TBL1XR1 [6, 7]. TBL1XR1 and
TBL1X both serve as specific adaptors for the
recruitment of the ubiquitin conjugating/19S
proteasome complex to the promoter in a ligand-dependent fashion, mediating the exchange
of corepressors for coactivatores [6, 7]. Unlike
TBL1XR1, TBL1X is still required for the transcriptional activation by NRs in the absence of
NCoR and SMRT. The data indicate that
TBL1XR1 is specifically required for the ubiquitylation and degradation of NCoR and TBL1X
may act on different corepressor complexes.
Further study identified CtBP1/2 as a specific
target of TBL1X [7]. The functions and the specificity of TBL1XR1 and TBL1X are regulated by
signaling specific phosphoration events at target gene promoters [7]. This differential specificity is also observed in the NCoR clearance
15

induced by the activation of Toll-Like Receptors
(TLRs) [33]. Our early study showed that
TBL1XR1 is also required for the degradation of
SMRT [23]. Additionally, the phosphorytion of
SMRT S2410 by IKKα is important for the dismissal of SMRT for the derepression of NF-κB
target genes, which concomitantly correlates
with the recruitment of TBL1XR1/TBL1X to the
target gene promoters, suggesting that TBL1XR1 is also important in the dismissal of the
SMRT complex for coactivator exchange [10].
Many signaling pathways in the higher eukaryotes are tightly regulated through a dual-repression “checkpoint” based on distinct corepressor complexes. The dedicated exchange factors
such as TBL1XR1 and TBL1X serve as sensors
for signal-specific dismissal of distinct corepressors, with specificity imposed by upstream
signaling pathways [7].
TBL1XR1 in Wnt-β-catenin signaling pathway
The Wnt-β-catenin signaling pathway is critical
for development, specification of cell fate, and
adult stem cell proliferation. The aberrant activation of this pathway has been implicated in
the tumorogenesis of several types of cancers
[34]. The Wnt target genes are silenced by the T
cell factor/lymphoid enhancing factor (TCF/
LEF) family protein and Groucho/TLE1 corepressor complex in the absence of signaling.
Upon activation of the Wnt-β-catenin signals,
β-catenin enters the nucleus and binds to the
TCF/LEF protein in displacing the corepressor
complexes and recruiting other co-activator
complexes to induce transcription [8, 9, 34].
Overexpression of TBL1XR1 or TBL1X in
HK293T cells can lead to significantly enhanced
β-catM (a mutant form of β-catenin)-stimulated
transcription. Depletion of TBL1XR1 or TBL1X
by siRNAs abolishes the activation of β-catenin
induced by lithium (LiCl) treatment or Wnt3a.
Wnt signaling induces the formation of a complex between β-catenin and TBL1X-TBL1XR1,
which is recruited to the Wnt target gene promoter. TBL1X can also bind to TCFs. The recruitment of TBL1X-TBL1XR1 and β-catenin to the
Wnt target gene promoter is mutually dependent. Furthermore, TBL1X andTBL1XR1 do not
affect the nuclear level of β-catenin and are not
responsible for degradation of corepressor
complexes. These findings indicate that unlike
their roles as exchange factors in NR-mediated
activation, TBL1X and TBL1XR1 are critical for
the recruitment of β-catenin to Wnt target gene
Am J Clin Exp Urol 2015;3(1):13-23
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promoters. TBL1X and TBL1XR1 are also
important for β-catenin mediated oncogenesis
[8]. Recent study shows that both TBL1X and
TBL1XR1 are subjected to sumoylation in a Wnt
signaling-dependent manner, which dismisses
TBL1X-TBL1XR1 from the NCoR complex and
enhances the formation of TBL1X-TBL1XR1-βcatenin complex [9]. The depletion of TBL1XTBL1XR1 or Inhibition of sumoylation may have
important implications in developing new strategies for inhibiting Wnt-beta-catenin-mediated
tumorigenesis.
TBL1XR1 in NF-κB pathway
NF-κB plays an important role in multiple cellular processes, including immune signaling,
inflammation, development, proliferation and
survival. Aberrant activation of NF-κB signaling
pathway has been implicated in autoimmunity,
chronic inflammation and cancer [35]. In
unstimulated cells, NF-κB is sequested in cytoplasm as an inactive form by binding to a family
of inhibitory proteins, IkB. Upon stimulation, IkB
is phosphorylated by IkB kinase (IKK) complex
and subject for subsequent proteasome-mediated degradation, allowing NF-κB to translocate
to the nucleus to initiate transcription [35]. In
unstimulated cells, p50 or p52 homodimers
repress NF-κB regulated genes through BCL-3
dependent and BCL-3 independent mechanisms. The activation of NF-κB regulated genes
is mediated by the exchange of BCL-3associated NCoR corepressor for the Tip60
coactivator complex. This pathway only regulates a small subset of NF-κB regulated genes
while the majority of NF-κB regulated genes are
regulated by the classical NF-κB heterodimer
complex [10]. Recent study reveals that both
TBL1X and TBL1XR1 are required for the NF-κB
mediated activation on canonical sites [6].
TBL1X is critical for the recruitment of p65 to
NF-κB target genes to mediate activation.
NF-κB transcription requires IKKalpha to phosphorylate SMRT on chromatin, stimulating the
exchange of corepressor for coactivator complexes. The recruitment of TBL1X-TBL1XR1 to
the target promoters coincides with SMRT
phosphorylation [10]. Moreover, TBL1XR1 can
directly interact with BCL-3 and is involved in
BCL-3 degradation through a GSK3 independent pathway [36]. These results suggest that
TBL1XR1 plays a critical role in NF-κB mediated
activation through both canonical and noncanonical pathways.
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TBL1XR1/HDAC3 corepressor complex is
important for mitotic spindle formation
Studies have shown that altered HDAC3 level
increases G(2)/M cells, suggesting a possible
role of HDAC3 in cell proliferation. Ishii et al [37]
showed that the HDAC3 complex, including
N-CoR, TBL1X, and TBL1XR1, is localized on
the mitotic spindle. Knockdown of HDAC3 or
N-CoR or inhibition of HDAC3 activity with
Trichostatin A results in a collapsed mitotic
spindle independent of transcriptional regulation, which can be rescued by wild-type HDAC3.
Inactivation of HDAC3 impairs kinetochoremicrotubule attachments without affecting the
kinetochores and the spindle assembly checkpoint. The studies suggest that acetylationdeacetylation of mitotic spindle components
may be essential for mitotic spindle function.
TBL1XR1 in normal hematopoiesis
CD34+CD38 - cells are considered as the earliest human hematopoietic progenitors. They
have the ability to initiate long term bone marrow culture in vitro and to reconstitute NOD/
SCID mice in vivo [38, 39]. We have found that
TBL1XR1 is expressed at a much higher level in
CD34+CD38 - cells compared to their mature
counterpart CD34+CD38+ cells. Northern blot
analysis has shown that TBL1XR1 mRNA is
expressed at a higher level in the tissues
enriched for early hematopoietic cells such as
fetal liver and bone marrow in comparison with
peripheral blood [23]. TBL1XR1 has been implicated in multiple intacellular signaling pathways important for stem cell fate determination
and proliferation such as Wnt pathway and
NOTCH pathway. Ebi, the Drosophila homologue of TBL1XR1, is required for maintenance
of photoreceptor neurons by suppressing proapoptotic gene expression [40]. This is confirmed by a recent report that TBL1XR1 mRNA
is upregulated after the exposure of neural
stem cells to ethanol [41]. We have shown that
overexpression of TBL1XR1 is able to induce
growth arrest [23]. These findings suggest that
TBL1XR1 may be important in the maintenance
of hematopoietic stem cells. Further studies in
this regard may be helpful in our understanding
its functions in hematopoiesis.
TBL1XR1 and intellectual disability
Intellectual Disability (ID) affects almost 3% of
the population and increasingly becomes a

Am J Clin Exp Urol 2015;3(1):13-23
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public health challenge [11]. It can be sporadic
or associated with other congenital abnormalities. Pons et al. reported an eight-year-old girl
with facial dysmorphism, speech delay, and
mild to moderate ID. Her mother displayed similar physical and intellectual features. Using
array-CGH (array comparative genomic hybridization) techniques, a 708 kb microdeletion at
3q26.32 region was identified in both patients,
which affects only TBL1XR1gene. Family studies revealed that the mother is a founder and
the pattern of inheritance is autosomal dominant [11]. The third case is a six-year-old girl
and she also has facial dysmorphism and mild
to moderate ID. In this patient, a 1.6 Mb deletion is identified in the 3q26.31q26.32 region
encompassing only TBL1XR1 gene [12]. The
three cases are very similar and possibly represent a new autosomal dominant syndrome
associated with TBL1XR1 haploinsufficiency.
This syndrome is characterized by facial dysmorphism (pointed chin, long philtrum, and thin
vermilion), speech delay, mild to moderate ID,
and lack of autistic behaviors.

teria for ASD. The mutation data replicate the
importance of a β-catenin-chromatin-remodeling network to ASD etiology [14].

Additionally, two cases are also identified in the
DECIPHER database [11]. The first patient has
autism, hearing impairment and spotty hyperpigmentation, who carries a 2.14 Mb deletion
encompassing the TBL1XR1 and KCNMB2
genes. The second case is characterized by ID,
ataxia, ASD (stereotypic behavior and self-mutilation) and dysmorphism (wide mouth, macrotia, prominent ears, hypertelorism, and downslanted palpebral fissures). This patient carries
four copy number variation (CNV) affecting several genes in addition to a 150 kb de novo deletion encompassing only TBL1XR1.

To identify genetic events implicating in cancer
progression, Kadota et al. conducted a comprehensive genetic evaluation of 161 primary
breast tumors (mostly invasive breast carcinomas) for gene amplifications [16]. Their findings
show that the level of TBL1XR1 protein is higher in the malignant cell lines MCF10CA1h and
MCF10CA1a than that in MCF10A, a normal
immortalized mammary epithelial cell line.
Depletion of TBL1XR1 in MCF10CA1h using
shRNA results in reduction of cell migration and
invasion as well as suppression of tumorigenesis in mouse xenografts [16]. A different study
confirms these findings by showing that
TBL1XR1is significantly upregulated in breast
cancer cell lines and 52.8% of primary breast
cancers cases in comparison with normal
breast tissues. This study also shows that the
level of TBL1XR1 protein expression is positively correlated with aggressive clinical behavior.
The patients with higher levels of TBL1XR1
expression have shorter overall survival compared to those with lower levels of expression.
Multivariate analysis indicates that TBL1XR1
overexpression is an independent prognostic
indicator for the survival of breast cancer
patients. They demonstrate that TBL1XR1 promotes tumor cell proliferation and tumorigenicity in breast cancer through the activation of
Wnt/β-catenin signaling pathway [17].

Recently, a whole exome sequencing (WES)
study identified recurrent mutations in patients
with autistic spectrum disorder (ASD), in which
two had de novo TBL1XR1 mutations [14]. Both
patients have ASD and severe ID, but neither of
them have any obvious dysmorphism or recurrent comorbidities. The TBL1XR1 mutations
occur at positions 282 (p.Leu282Pro) and 397
(p.Ile397Serfs*19), respectively. The third case
is a Japanese girl who had a de novo TBL1XR1
mutation (p.Gly70Asp) located in the F-box-like
domain [13]. She presented with West syndrome, Rett syndrome-like and autistic features. Based on the guidelines in the diagnostic
manual (DSM-IV) of the American Psychiatric
Association, this case meets the diagnostic cri17

TBL1XR1 in cancers
TBL1XR1 dysregulations in solid tumors
Liu et al. identified TBL1XR1 as a differentially
expressed gene in human primary lung squamous cell carcinoma (LSCC) by comparing lung
tumor tissues and normal bronchial epithelial
tissues using suppression subtractive hybridization method [15]. Quantitative real-time PCR
(q-PCR) analysis showed upregulation of
TBL1XR1 mRNA in 75% of LSCC cases in the
validation set. The overexpression of TBL1XR1
protein was confirmed by western blot analysis
in 53.3% of LSCC tumor samples, 5 lung cancer
cell lines, and 1 human immortalized bronchial
epithelial cell line [15]. Deletions at human
3q26.32 encompassing TBL1XR1 gene have
been previously detected by array-based comparative genomic hybridization (aCGH) in
human immortalized bronchial cell lines.

Am J Clin Exp Urol 2015;3(1):13-23
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Similar findings are also observed in cervical
cancer, nasopharyngeal carcinoma (NPC) and
esophageal squamous cell carcinoma (ESCC)
[18-20]. Upregulation of TBL1XR1 in NPC cells
leads to resistance of the tumor cells to cisplatin by activating the NF-κB pathway, which is
associated with poor prognosis [19]. In cervical
cancer, upregulation of TBL1XR1 is significantly
associated with recurrence. Forced expression
of TBL1XR1 in cervical cancer cell lines (Hela
and Siha) promotes invasion by inducing epithelial-mesenchymal transition through the
activation of NF-κB and Wnt/β-catenin signalling pathways [18]. TBL1XR1 promotes lymphangiogenesis and lymphatic metastasis in
ESCC by inducing the expression of VEGF-C.
The association between the TBL1XR1 expression and VEGF-C expression is not only seen in
ESCC but also observed in gastric, colonic and
breast cancers based on the published database [20].
Studies have shown that depletion of TBL1XR1
by shRNA in HT-29 cells, a colon cancer cell line
significantly reduces the recruitment of β-catenin to its target gene promoters, such as
AXIN2 and c-MYC, and inhibits the endogenous
expression of c-MYC, MMP7 and ITF2, leading
to inhibition of tumor cell invasion through the
Matrigel-coated membrane and suppression of
tumor growth in nude mice [8].
Our studies have shown that TBL1XR1acts as a
coactivator of Androgen receptor (AR) in prostate cancer cells and the activation is dependent on both phosphorylation and 19S proteasome machinery. We also show that TBL1XR1
physically interacts with AR and directly occupies the androgen-response elements of the
affected AR target genes in an androgendependent manner. TBL1XR1 is primarily localized in the nucleus in benign prostate cells and
nuclear expression is significantly reduced in
prostate cancer cells in culture. Similarly, in
human tumor samples, the expression of
TBLR1 in the nucleus is significantly reduced in
the malignant glands compared with the surrounding benign prostatic glands. Stable ectopic expression of nuclear TBL1XR1 leads to
androgen-dependent growth suppression of
prostate cancer cells in vitro and in vivo by
selective activation of androgen-regulated
genes associated with differentiation and
growth suppression, but not cell proliferation of
the prostate cancer [21, 42]. TBL1XR1 gene
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amplification has been identified in invasive
prostate cancer, which correlates with disease
progression. PTEN loss is the most frequent
aberration in progressers (57%); followed by
TBL1XR1 gain (29%) and MYC gain (14%).
Based on this study, it would detect progressers with 86% sensitivity and 100% specificity
using a probe set consisting of PTEN, MYC, and
TBL1XR1 [43].
Four novel translocations involving the TBL1XR1 gene have been identified in an effort to
study the landscape of kinase fusion in cancers
[44]. They include one TBL1XR1-RET fusion
and three TBL1XR1-PIK3CA fusions. Two of the
TBL1XR1-PIK3CA fusions are found in 1,072
breast cancer (invasive) samples and one in
335 prostate adenocarcinoma samples. Both
tissue types are hormone driven and ranked
among the highest for TBL1XR1 mRNA expression across all normal tissues. The LisH motif in
TBL1XR1 is capable of dimerization, therefore
likely leading to RET or PIK3CA activation.
TBL1XR1 dysregulation in lymphomas
Using WES approach, a novel TBL1XR1/TP63
gene fusion has been recently identified in diffuse large B-cell lymphoma (DLBCL) [45],
peripheral T-cell lymphoma (PTCL) [46], and follicular lymphoma (FL) [45]. The gene fusions
result from a chromosomal rearrangement
between TBL1XR1 gene (3q26.32) and TP63
gene (3q28). In most cases, the exons 1-7 of
TBL1XR1 fuse in frame to the exons 4-8 or 4-10
of TP63. The exon 14 or exon 4 of TBL1XR1 is
involved in the remaining cases including two
DLBCLs and one FL [45]. The TBL1XR1/TP63
fusion is reported in 5% of germinal center
B-cell like (GCB) DLBCL and appears to be
exclusive for the GCB type. It is also present in
PTCL in a similar percentage, but this fusion is
rare event in FL. P63 has two main classes of
isoforms, TAp63 and ΔNp63. TAp63 has an
N-terminal transactivation domain with tumor
suppressor activity, whereas ΔNp63 contains a
truncated N-terminal domain that has been
proposed to confer oncogenic properties. The
expression of the TBL1XR1/TP63 fusion was
5.2 fold higher than the wild-type [45]. The
TBL1XR1/TP63 protein may function similarly
to ∆N-TP63, antagonizing the action of TP53,
TA-TP63, and TA-TP73. TP63 rearrangement in
PTCLs is associated with significantly higher
mean immunohistochemistry scores for p63,
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ki67 and CD30. Patients with PTCLs carrying
TP63 rearrangements have significantly inferior
overall survival compared with patients without
TP63 rearrangements. In one case, the fusion
was retrospectively found in T cells before the
clinical diagnosis of mycosis fungoides, suggesting that it is an initiating event in lymphomagenesis [47]. It has been speculated that
this abnormality may not only provide a proliferative advantage but also resistance to the
genotoxic stress induced by chemotherapy
[45].
WES and array-based comparative genomic
hybridization (aCGH) have been proven to be
effective tools in identifying small genomic
alterations in formalin-fixed paraffin-embedded
(FFPE) specimens. Using WES analysis, recurrent mutations of TBL1XR1 have been identified in 19% of primary central nervous system
lymphoma (PCNSL) cases [48, 49]. The mutations are clustered in three main regions: LisH
domain, F-box like domain and the C-terminus.
Interestingly, one mutation at the C-terminus
affects the potential phosphorylation site.
MYD88 mutations are also frequent in the
same patient group. Moreover, a novel missense mutation in TBL1XR1 (T229R) was identified in a patient with Sezary syndrome, which
converts a neutral to a hydrophilic amino acid
[50]. Since MYD88 and TBL1XR1 both are
involved in NF-κB signaling pathway, it is possible that TBL1XR1 mutations lead to aberrant
activation of NF-κB pathway and subsequent
lymphomagenesis. In one study, focal deletions
affecting sole TBL1XR1 gene are identified in
three out of nine PCNSL cases by aCGH analysis [51]. Similar genomic alterations are also
reported in a small subset of de novo DLBCL
cases. Like the B-lymphoblastic leukemia with
deletions of TBL1XR1, these patients may
develop resistance to steroid therapy due to
loss of normal functions.
TBL1XR1 abnormalities in acute leukemias
Focal deletions of TBL1XR1 have been identified in 3 to 10% of acute lymphoblastic leukemia (ALL) patients [52]. The ETV6-RUNX1
fusion is the molecular consequence of the
t(12;21)(p13;q22), which is seen in approximately 25% of children with B-ALL. Focal deletions of TBL1XR1 have been observed in 15%
of these cases and appear to be exclusive for
this subtype. A q-PCR analysis showed that the
19

TBL1XR1 mRNA is significantly under-expressed and deletion of TBL1XR1 compromised
the function of SMRT/N-CoR in the appropriate
control of gene expression [52-54]. Deletions
of TBL1XR1 are significantly more common in
B-ALL patients who relapse compared with
those remaining in complete remission. Recently, a study has shown that knockdown of
TBL1XR1 in B-ALL cell lines results in reduced
glucocorticoid receptor recruitment to glucocorticoid responsive genes and ultimately
decreased glucocorticoid signaling caused by
increased levels of NCoR and HDAC3. The
resistance is specific for glucocorticoid agonists. Treatment with the HDAC inhibitor SAHA
restores sensitivity to prednisolone in TBL1XR1depleted cells [22].
A novel t(3;17)(q26.32;q21) translocation has
recently been reported in three patients with
acute promyelocytic leukemia (APL). The rearrangement results in a fusion product between
exons1-3 of TBL1XR1 gene and exons 6-8 of
RAR gene. The TBL1XR1/RARα protein is predominantly localized in the nucleus and can
form homodimers or heterodimers with retinoid
X receptor α. The fusion protein can act as transcriptional activator in the presence of ligand,
but the transactivity is much weaker than
RARα. The TBLR1-RARα product exhibits diminished transcriptional activity as a result of the
recruitment of more transcriptional corepressors compared with RARα. In the presence of
pharmacologic doses of ATRA, TBLR1-RARα
could be degraded, and its homodimerization
was abrogated [55].
Therapeutic potentials of targeting TBL1XR1related pathways
Disruption of interactions between TBL1XR1
and NCoR has been shown to inhibit gene
repression by unliganded NRs [3]. Overexpression of the TBL1XR1-interacting domain of
NCoR (DN-RD1) in frog oocytes can disrupt the
interaction between endogeneous NCoR and
TBL1XR1 and reverse the repression by unliganded RAR/RXR [4]. Knockdown of TBL1X or
TBL1XR1 by shRNA in cell lines can block the
binding of β-catenin to TCF4 and repress the
transcription of WNT-β-catenin target genes,
leading to inhibition of cell proliferation [8].
These research findings lay the foundation for
development of therapies targeting these platforms. A recent pre-clinical study, testing
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effects of BC2059 (β-Cat Pharmaceuticals), a
small anthraquinone oxime-analog molecule on
the growth of AML stem and blast progenitor
cells (BPCs), provided promising results.
Treatment with BC2059 disrupts the binding of
β-catenin to TBL1X and promotes proteasomal
degradation of β-catenin, inhibiting the expression of the genes of Wnt/β catennin pathway
both in the cultured cell lines and in primary
AML BPCs. It also shows dose dependent inhibition of growth and induces apoptosis of cultured and CD34+ pAML BPCs expressing FLT3ITD, but not of normal CD34+ bone marrow
progenitor cells. BC2059 enhances cell death
induced by transient knockdown of TBL1X or
β-catenin in MOLM13 cells and induces apoptosis in MOLM13-TKIR cells (a FLT3 antagonistresistant cell line). More importantly, BC2059
treatment (by IV injection) exerts potent in vivo
anti-AML activity and significantly improved the
survival of immune depleted mice engrafted
with cultured and patient-derived pAML BPCs.
Furthermore, BC2059 and FLT3-antagonist
quizartinib or ponatinib synergistically induces
apoptosis of the FLT3-ITD expressing cultured
cells (MOLM13 and MV4-11) and primary AML
BPCs but not of normal CD34+ progenitor cells.
Collectively, these findings support that the targeted therapy is a promising approach in treating AML [56].
Summary
TBL1XR1 is an evolutionarily conserved protein
that shares high structural and functional similarities from yeast to human. Three human
homologues have been identified. TBL1XR1 is
an intrinsic component of the SMRT/NCoR
corepressor complexes, and it is also required
for transcriptional activation by NRs and other
regulated TFs. It is important for the activation
of multiple intracellular signaling pathways,
such as Wnt-β-catenin, NF-κB, and Notch. It is
preferentially expressed in human hematopoietic stem cells and may be critical for the maintenance of stem cells. Germline mutations in
TBL1XR1 or recurrent mutations are associated with intellectual disability. Dysregulation of
TBL1XR1 has been observed in a variety of
neoplastic conditions. TBL1XR1 appears to be
multifunctional and its functions are cell typeand context- dependent. However, its exact
functions are still not clear. A recent pre-clinical
study shed light on the therapeutic potential of
targeting TBL1XR1-related pathways in cancer
treatment.
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